Global Biosimilars Market Regulations & Pipeline Insight

Description: The evolution of biosimilars has currently reached different stages across the world. Owing to variable clarity in the guidelines and diverse regulatory pathways, various definitions of biosimilars (or the broader group of follow-on biologics) have emerged across countries. Till now the European region has the best-established framework for biosimilars. The US is currently almost aligned to the European standards. Biosimilars are also known as follow on biologics in the US and subsequent entry biologics in Canada, are biologic products which are approved in a country, which has an abbreviated approval process for biologic products which references an originator biologic in the regulatory submission.

The global biosimilars market is categorized into monoclonal antibody biosimilars (mAbs), insulins, interferons, erythropoetins, filgrastim, somatropin and follicle stimulating hormone (FSH). Among the segments of the biosimilars market, the monoclonal antibodies (mAbs) and insulin market would witness maximum growth, with these two segments accounting for a dominant share of more than 40% of the total global biosimilars market by 2018. Additionally, with the mAbs having one of the strongest R&D pipeline in the biologics market, it is expected that many new next-generation technologies which would push mAb therapeutics into newer areas such as solid tumours, cardiovascular and neurological disorders would be introduced into the market.

In terms of innovation in the biosimilars, it is most likely that the future market would witness the introduction of follitropins, interferons and low molecular weight heparins products, in addition to mAbs. Also, it is expected that some pharmaceutical companies could increasingly start focusing on specific therapeutic classes based on their capacity to manufacture and their strategic fit.

Almost all the countries across the globe are currently experiencing an increase in their ageing population with a parallel increase in the incidence of chronic diseases. However, an increase in the demand for high quality healthcare is generally associated with the issue of controlling spiraling healthcare expenditure. With the regulated and streamlined introduction of biosimilars into the market, it is most likely that there would be an increase in the accessibility and affordability of the much in demand biologic medicines. The next few years are likely to witness a new set of complex biosimilars products being developed owing to a significant number of leading brands of biologic drugs losing their patents by 2020.

"Global Biosimilars Market Regulations & Pipeline Insight" Report Highlights:

- Market Overview
- Detailed Regulatory Pathways For 12 Countries/Regions
- Global Biosimilars Pipeline by Phase, Indication, Company & Country
- Biosimilars Pipeline: 276 in Development Phase
- Majority Biosimilars in Preclinical Phase: 76 Biosimilars
- Marketed Biosimilars by Indication, Company & Country: 113 Biosimilars

Contents: 1. Global Biosimilars Market Outlook
   1.1 Market Overview
   1.2 Clinical Pipeline Insight

2. Global Biosimilars Market Dynamics
   2.1 Favorable Market Parameters
   2.2 Issues to be Discussed

3. Global Biosimilars Market Future Growth Opportunities

4. Regulatory Pathways for Development & Marketing of Biosimilars
   4.1 Australia
   4.2 Canada
   4.3 Europe
   4.4 Japan
4.5 India
4.6 Malaysia
4.7 Saudi Arabia
4.8 Singapore
4.9 South Africa
4.10 South Korea
4.11 Turkey
4.12 US

5. Global Biosimilars Pipeline by Phase, Indication, Company & Country
   5.1 Unknown
   5.2 Research
   5.3 Preclinical
   5.4 Clinical
   5.5 Phase-0
   5.6 Phase-I
   5.7 Phase-I/II
   5.8 Phase-II
   5.9 Phase-III
   5.10 Preregistration
   5.11 Registered


7. Suspended & Discontinued Biosimilars Pipeline by Phase, Indication, Company & Country
   7.1 No Development Reported
   7.2 Discontinued
   7.3 Suspended

8. Competitive Landscape
   8.1 Actavis
   8.2 Amgen
   8.3 BioXpress Therapeutics
   8.4 Boehringer Ingelheim
   8.5 Biocon
   8.6 Bio Sidus
   8.7 Dong-A Pharmaceutical
   8.8 Harvest Moon Pharmaceuticals
   8.9 Inbiopro Solutions
   8.10 Mylan
   8.11 Reliance Life Sciences
   8.12 Sandoz International

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2933277/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Biosimilars Market Regulations & Pipeline Insight
Web Address: http://www.researchandmarkets.com/reports/2933277/
Office Code: SCBR8F5K

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>USD 2400</td>
</tr>
<tr>
<td>Single User</td>
<td>USD 2400</td>
</tr>
<tr>
<td>CD-ROM</td>
<td>USD 2800 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td>Hard Copy</td>
<td>USD 3000 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>USD 4200</td>
</tr>
<tr>
<td>Enterprisewide</td>
<td>USD 4200</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
First Name: ____________________________________ Last Name: ____________________________________
Email Address: *
______________________________________________________________
Job Title: ____________________________________________________
Organisation: _________________________________________________
Address: _____________________________________________________
City: _________________________________________________________
Postal / Zip Code: ____________________________________________
Country: _____________________________________________________
Phone Number: _______________________________________________
Fax Number: __________________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World